Acurx Pharmaceuticals Inc... (ACXP)
Acurx Pharmaceuticals Statistics
Share Statistics
Acurx Pharmaceuticals has 22.4M shares outstanding. The number of shares has increased by 39.31% in one year.
| Shares Outstanding | 22.4M |
| Shares Change (YoY) | 39.31% |
| Shares Change (QoQ) | 30.49% |
| Owned by Institutions (%) | 8.62% |
| Shares Floating | 19.45M |
| Failed to Deliver (FTD) Shares | 496 |
| FTD / Avg. Volume | 0.18% |
Short Selling Information
The latest short interest is 474.48K, so 2.43% of the outstanding shares have been sold short.
| Short Interest | 474.48K |
| Short % of Shares Out | 2.43% |
| Short % of Float | 2.87% |
| Short Ratio (days to cover) | 12.59 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -0.38. Acurx Pharmaceuticals's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -0.38 |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | 0.02 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Acurx Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0, with a Debt / Equity ratio of 0.
| Current Ratio | 0 |
| Quick Ratio | 0 |
| Debt / Equity | 0 |
| Debt / EBITDA | - |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-3.53B |
| Employee Count | 4 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -76.83% in the last 52 weeks. The beta is -1.35, so Acurx Pharmaceuticals's price volatility has been lower than the market average.
| Beta | -1.35 |
| 52-Week Price Change | -76.83% |
| 50-Day Moving Average | 0.55 |
| 200-Day Moving Average | 1.4 |
| Relative Strength Index (RSI) | 41.99 |
| Average Volume (20 Days) | 269.66K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | 0 |
| Net Income | -14.1B |
| EBITDA | 0 |
| EBIT | n/a |
| Earnings Per Share (EPS) | -872.54 |
Balance Sheet
The company has 3.71M in cash and 0 in debt, giving a net cash position of 3.71M.
| Cash & Cash Equivalents | 3.71M |
| Total Debt | 0 |
| Net Cash | 3.71M |
| Retained Earnings | -67.32B |
| Total Assets | 3.86M |
| Working Capital | 615.12K |
Cash Flow
In the last 12 months, operating cash flow was -10.38B and capital expenditures 0, giving a free cash flow of -10.38B.
| Operating Cash Flow | -10.38B |
| Capital Expenditures | 0 |
| Free Cash Flow | -10.38B |
| FCF Per Share | -642.41 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ACXP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ACXP is $12, which is 3057.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $12 |
| Price Target Difference | 3057.9% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -31.53 |
| Piotroski F-Score | 1 |